Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
breast cancer
Fierce Pharma
FDA's surprise approval of AZ's oral SERD sets new paradigm
Etcamah’s approval “validates an entirely new treatment paradigm of ctDNA-guided intervention before radiographic progression.”
Angus Liu
Sep 8, 2026 10:35am
Guardant wins FDA nod for test guiding AstraZeneca’s Etcamah
Sep 7, 2026 2:08am
Fierce Pharma
Celcuity set to be Big Pharma 'strategic target' after approval
Jul 14, 2026 4:56pm
Roche oral SERD's 1st-line miss spurs new adjuvant trial
Jun 2, 2026 12:45pm
ASCO: Why Celcuity dares to dream of becoming $10B company
Jun 2, 2026 8:01am
ASCO: BMS' bispecific ADC puts TROP2 drugs on notice
Jun 2, 2026 8:00am
